POPULARITY
It is the final episode of our Challenging Cases in Emergency General Surgery series and we're diving into another dreaded topic: the complex abdominal wall. This structure is a daily partner to the general surgeon—but when things go wrong, it can quickly become our biggest challenge. In this episode, we'll walk through the emergency presentation of a patient with multiple prior hernia repairs and mesh placements, and how these complicate diagnosis and management. From imaging pearls to OR decision-making and post-op dilemmas, this episode covers it all. We round things off with a fun game (as always!) and some hot takes on abdominal wall strategies in emergency general surgery. Whether you're an EGS surgeon, trainee, or surgical enthusiast, this episode is packed with practical insights, decision-making frameworks, and real-world nuance. Hosts: - Dr. Ashlie Nadler - Dr. Jordan Nantais - Dr. Graham Skelhorne-Gross Learning Objectives: - Identify key factors to assess in patients presenting with complex abdominal wall problems, including detailed surgical history, hernia characteristics, and signs of complications. - Discuss the role of imaging, particularly CT scans, in evaluating patients with ventral hernias and bowel obstruction, with a focus on identifying transition points and signs of strangulation. - Outline the surgical approach to incarcerated incisional ventral hernias, including pre-operative considerations, operative techniques, and management of threatened bowel. - Recognize the importance of patient-specific factors and interdisciplinary collaboration in the management of complex abdominal wall cases, including the role of pre-habilitation and hernia specialists. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
Prof. Zohar Habot-Wilner (Tel Aviv University) chairs a rich discussion with Prof. Sofia Androudi (University of Thessaly, Greece) and Prof. Sarah Touhami (University of Sorbonne) on managing retinal and uveitic diseases during pregnancy. They explore safe diagnostic tools, therapeutic dilemmas like Ranibizumab vs. Ozurdex, and the effects of pregnancy-related hormonal shifts—highlighting the importance of multidisciplinary collaboration in high-risk cases
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN Recorded on March 18, 2025 Angela Dispenzieri, MD Consultant, Division of Hematology Serene M. and Frances C. Durling Professor of Medicine and of Laboratory Medicine and Pathology Mayo Clinic Rochester, MN Join us as we dive into in the complex care of amyloid and myeloma with Dr. Angela Dispenzieri from Mayo Clinic Rochester, Minnesota. She explains the diagnosis and explores the differences between amyloid and myeloma. Discussion on treatment strategies for complex cases, side effects of therapies, and difficult conversations with patients, provide practical information on patient care. Tune in today to learn more about the complexities of myeloma. This episode is supported by GSK plc.
Dr. Sal Ruggiero, oral and maxillofacial surgeon, discusses the complexities of dental implants in specialized patient groups, including those with cleft lip and palate, teenagers requiring implants under unusual circumstances and oral cancer patients' post-radiation therapy. His insight highlights the importance of individualized treatment plans and advanced surgical techniques in managing these complex cases.
Join experts from 4 different institutions (Kiona Allen MD of Lurie Children's, Alex Floh MD of Sick Kids, Sushma Reddy MD of Lucile Packard Hospital and Lisa Grimaldi MD of Phoenix Children's) as they discuss their management of common but challenging cases in the CVICU such as feeding a pre-op truncus and fever in an infant on prostaglandin. Hosts: Deanna Tzanetos MD (Norton Children's) and Lillian Su MD (Phoenix Children's). Editor/Producer: Lillian Su MD
Sometimes things aren't as straight forward as they seem. We must take it upon ourselves to do the research and see what is relevant to what is presented in front of us. Joe has over 10 years of experience being a PTA and is here to share his experience in gaining critical thinking skills as well as how he has applied them. Everyone will have a different approach, but as we know, critical thinking is a must have skill in this field. Let's get right into it. Thank you so much for listening and don't forget to check out our socials!
In this episode, host Dr. Aaron Fritts interviews interventional radiologists Dr. Kumar Madassery and Dr. Shelly Bhanot about catheter shapes and when to use each type in basic and challenging cases. --- CHECK OUT OUR SPONSOR Cook Medical https://www.cookmedical.com/divisions/vascular-division/ --- SHOW NOTES Kumar serves as an Associate Professor and Director of Peripheral Vascular Interventions/Critical Limb Ischemia and Shelly is a PGY-6 IR resident at Rush University Medical Center in Chicago, IL. Kumar and Shelly walk us through a number of different catheters and techniques, along with tips that they have learned from their experiences in the cath lab. They pair complex and challenging anatomy with catheter types, and they describe their reasoning behind different approaches. After going through case-based examples, both Kumar and Shelly share advice on how trainees can become more familiar with tools on the back table. These include observing supply shelves, asking questions, and learning from IR techs and device representatives. We conclude the episode by emphasizing the power of teaching and how experience is a big factor in becoming more and more familiar with all the catheters that are available to our specialty. Disclaimer: The content, information, opinions and viewpoints contained in this presentation are for educational purposes only. Some opinions expressed may represent those of the speaker and are based on their own clinical experience in their practice. This information is not meant or intended to serve as a substitute for a healthcare professional's clinical training, experience or judgment. Guest speakers are paid consultants of Cook Medical. Always refer to the Instructions for Use for complete prescribing information including indications for use, warnings, precautions, adverse events and deployment/use instructions.
Bad things happen in medicine. Sometimes it can't be avoided, but what we can do is try to prepare ourselves the best we can. On today's episode, Dr. Alicia Power & Dr. Maryna Mammoliti discuss what we can do in such events, the concept of radical acceptance, and how we can plan both as individuals and organizations to support each other during such times. In conjunction, we have created an Adverse Events Plan Template to help you build a tailored framework for moving forward. Resources: Adverse Events Plan Template Feedback: Please take a moment to fill out this very short anonymous survey (>1 minute). We want to optimize Pregnancy for Professionals to suit your needs, so any feedback is very valuable and much appreciated!
It's another session of CardioNerds Rounds! In these rounds, Dr. Jenna Skowronski (Chief FIT at University of Pittsburgh) and Dr. Natalie Stokes (Formerly FIT at University of Pittsburgh and now General Cardiology Faculty at University of Pittsburgh) join transformational leader, educator and researcher, Dr. Mary Norine Walsh (Director of Heart Failure and Transplantation at Ascension St. Vincent Heart Center and Program Director of AHFT at St. Vincent) to discuss cardio-obstetrics and heart failure cases. Amongst her many accomplishments, Dr. Walsh is past president of the American College of Cardiology, Deputy Editor of JACC Case Reports, and a preeminent voice and thought leader in women's cardiovascular health. Audio editing by CardioNerds academy intern, Pace Wetstein. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Cardio-Obstetrics and Heart Failure Case 1 Synopsis: A woman in her earlier 30s, G1P1, with a history significant for peripartum cardiomyopathy presents to clinic for pre-conception counseling. Her prior pregnancy was in her late 20s with an uneventful pre-natal course and a spontaneous vaginal delivery at 37w2d. Two weeks after delivery, she experienced symptoms of heart failure and was found to have a new diagnosis of HFrEF. At that time TTE showed LVEF 30-35%, LVIDd 5.1cm (top normal size), diffuse hypokinesis. At that time, she was diuresed and discharged on metoprolol succinate 25mg po daily and furosemide 20mg po daily. She had one follow up visit 6 months postpartum and the furosemide was discontinued. Today in your office, she has NYHA Class I symptoms with no signs of symptoms of congestion. She walks daily and does vigorous exercise 1-2 times per week, while remaining on metoprolol. Repeat TTE with LVEF 45-50% and similar LV size. She would like to have another child and was referred to you for counseling. Case 1 Rounding Pearls: Dr. Walsh discussed extensively the importance of full GDMT in this patient who was initially undertreated with only a beta blocker. If patients are breastfeeding, clinicians should consider the addition of ACE-Inhibitor and Spironolactone. Otherwise, if not breastfeeding, they should receive maximally tolerated doses of full GDMT. For more details on medical therapy for Heart Failure during pregnancy and after, refer to this previous CardioNerds Episode with Dr. Julie Damp. Patients with peripartum cardiomyopathy are at highest risk of worsening LV systolic function when they have persistent LV systolic dysfunction from their initial diagnosis. In this circumstance, shared decision making is paramount. These patients should receive counseling on contraception and risk of pregnancy on worsening LV function, death, & fetal demise. In addition, counseling includes discussing with patients limited options in some states for complete, comprehensive reproductive care, including pregnancy termination. If patients with prior peripartum cardiomyopathy do become pregnant, a team-based approach including cardiologists, maternal fetal medicine, and obstetrics (amongst other team members) is essential to determine care & delivery timing/method. These patients should also be examined for signs of decompensation throughout the pregnancy, including rales, S3 or a reported history of PND.
It's another session of CardioNerds Rounds! In these rounds, Dr. Karan Desai (Formerly FIT at University of Maryland Medical Center and currently faculty at Johns Hopkins School of Medicine) joins Dr. Dan Burkhoff (Director of Heart Failure, Hemodynamics and MCS Research at the Cardiovascular Research Foundation) to discuss mechanical circulatory support options through the lens of pressure-volume loops! Dr. Burkhoff is the author of Harvi, an interactive simulation-based application for teaching and researching many aspects of ventricular hemodynamics. Don't miss this wonderfully nerdy episode with a world-renowned expert in hemodynamics and MCS! Audio editing by CardioNerds Academy Intern, student doctor Chelsea Amo Tweneboah. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Hemodynamics and Mechanical Circulatory Support Case Synopsis: Case SynopsisWe focused on one case during these rounds. A man in his mid-50s presented to his local community hospital with 3 days of chest pain, nausea, and vomiting. He appeared ill in the emergency room with HR in the 150s, BP 90/70s and ECG demonstrating inferior ST elevations. He was taken emergently to the catheterization lab and received overlapping stents to his right coronary artery. Over the next 24 hours, he developed a new harsh systolic murmur heard throughout his precordium and progressed to cardiogenic shock. Echocardiogram demonstrated a large basal inferoseptum ventricular septal rupture. From this point, we discussed the hemodynamics of VSR and MCS options. Case Takeaways Dr. Burkhoff took us through the hemodynamics of VSR with pressure-volume loops to better understand the pathology and impact of various MCS options. Of note, there are no MCS devices specifically approved to treat acute ventricular septal rupture. In regards to the acute hemodynamic effects of a VSR (an abrupt left to right shunt), there are several aspects to note. First, the effective LV afterload is reduced; however, there is less “forward flow” as well and as a consequence, decreased left-sided cardiac output (“Qs”) and blood pressure. At the same time, flow through the pulmonary artery increases (the “Qp”). Additionally, due to the abrupt shunt flow, there is increased RV “loading” with increasing central venous pressure and pulmonary artery pressure. The hemodynamic priorities in treating patients with cardiogenic shock and VSR are to normalize blood pressure, cardiac output, and oxygen delivery, while attempting to minimize shunt flow to allow healing. However, medications and MCS are unlikely to completely normalize hemodynamics. For instance, if the patient was placed on peripheral VA ECMO, while total CO and BP may increase, flow across the VSR could also increase at high ECMO flows (e.g., by introducing more LV afterload). In patients with persistent cardiogenic shock and VSR, short-term MCS to divert flow away from the shunt can be an effective strategy. LV-to-aorta or LA-to-arterial MCS may provide the best single-device hemodynamic profiles by decreasing shunt flow, reducing pulmonary capillary wedge pressure, and improving blood pressure. Surgical and percutaneous VSD repair are the definitive treatment options. If able to stabilize patients and pursue delayed repair,
It's another session of CardioNerds Rounds! In these rounds, Dr. Loie Farina (Advanced Heart Failure and Transplant Fellow at Northwestern University) joins Dr. Jane Wilcox (Chief of the Section of Heart Failure Treatment and Recovery at Northwestern University) to discuss the nuances of HFpEF diagnosis and management. Dr. Wilcox is also the Associate Director of the T1 Center for Cardiovascular Therapeutics in the Bluhm Cardiovascular Institute and Director of the Myocardial Recovery Clinic at Northwestern University. Dr. Wilcox is a prolific researcher, clinician, and thought leader in Heart Failure and we are honored to have her on CardioNerds Rounds! Notes were drafted by Dr. Karan Desai. Audio editing by CardioNerds Academy Intern, student doctor Akiva Rosenzveig. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Antithrombotic Management with Dr. Deepak Bhatt Case #1 Synopsis: A woman in her 80s with a history of HFpEF presented with worsening dyspnea on exertion over the course of a year but significantly worsening over the past two months. Her other history includes prior breast cancer with chemotherapy and radiation therapy, permanent atrial fibrillation with AV node ablation and CRT-P, and CKD Stage III. She presented for an outpatient RHC with exercise to further characterize her HFpEF. Her echo showed normal LV size, no LVH, LVEF of 50%, decreased RV systolic function, severe left atrial enlargement, significantly elevated E/e' and mild MR. Right heart catheterization showed moderately elevated bi-ventricular filling pressures at rest but with passive leg raise and Stage 1 exercise the wedge pressure rose significantly. We were asked to comment on management. Case #1 Takeaways Amongst the things that were discussed were the role of specific therapies in symptomatic patients with HFpEF. In patients with HFpEF and documented congestion, they will require diuretic therapy for symptomatic relief. But in addition to diuretic therapy, we discussed starting HFpEF-specific therapies. Amongst, those specific therapies mineralocorticoid receptor antagonist (MRA) and sodium-glucose co-transporter 2 (SGLT2) inhibitor. In multiple trials that have included patients with HFPEF, SGLT2i have reduced the risk of hospitalization. This includes the EMPEROR-PRESERVED Trial (see the CardioNerds Journal Club discussion on the trial) in which nearly 6000 patients with NYHA Class II-IV symptoms, EF > 40% and elevated NT-proBNP with a prior HF hospitalization within the past 12 months were randomized to Empagliflozin or placebo. The primary outcome – death from CV causes or hospitalization for Heart Failure – was significantly lower in the SGLT2i arm (13.8% vs 17.1%, 95% CI 0.69-0.90, P 45% to receive either spironolactone or placebo. The primary endpoint (death from CV cause, aborted cardiac arrest, or hospitalization for HF) was not statistically different between treatment arms. Of note, however, there were concerns for regional differences which is outlined well in this NEJM Evidence piece. Case #2 Synopsis: A woman in her 70s with history of hypertension, obesity,
How confident are you at identifying patients with hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence? Credit available for this activity expires: 11/28/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/983866?ecd=bdc_podcast_libsyn_mscpedu
Featuring perspectives from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda, including the following topics: Front-Line Chronic Lymphocytic Leukemia (CLL; Standard-Risk Patients) — Anthony R Mato, MD, MSCE (0:00) CLL in 2022: Front-Line Therapy for Patients with High-Risk Disease — Danielle Brander, MD (28:50) Fixed-Duration Targeted Therapy for CLL — William G Wierda, MD, PhD (59:26) Novel Investigational Agents and Strategies for CLL — Matthew S Davids, MD, MMSc (1:13:11) CME information and select publications
Proceedings from an educational event held in partnership with the 2022 Pan Pacific Lymphoma Conference, featuring perspectives on the management of chronic lymphocytic leukemia from Drs Danielle Brander, Matthew Davids, Anthony Mato and William Wierda.
It's another session of CardioNerds Rounds! In these rounds, Dr. Priya Kothapalli (Interventional FIT at University of Texas at Auston, Dell Medical School) joins Dr. Deepak Bhatt (Dr. Valentin Fuster Professor of Medicine and Director of Mount Sinai Heart) to discuss the nuances of antithrombotic therapy. As one of the most prolific cardiovascular researchers, clinicians, and educators, CardioNerds is honored to have Dr. Bhatt on Rounds, especially given that Dr. Bhatt has led numerous breakthroughs in antithrombotic therapy. Come round with us today by listening to the episodes of #CardsRounds! Audio editing by CardioNerds Academy Intern, Dr. Christian Faaborg-Andersen. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Antithrombotic Management with Dr. Deepak Bhatt Case #1 Synopsis: A woman in her early 70s with a history of hypertension, hyperlipidemia, and paroxysmal atrial fibrillation presented with sudden-onset chest pressure and diaphoresis while at rest and was found to have an acute thrombotic 99% mid-LAD occlusion. The patient received OCT-guided PCI with a single drug-eluting stent. We discussed what the appropriate antithrombotic strategy would be for a patient with recent acute coronary syndrome and atrial fibrillation. Case #1Takeaways According to the recent 2021 revascularization guidelines, in patients with atrial fibrillation undergoing PCI and taking oral anticoagulant therapy, it is recommended to discontinue aspirin after 1 to 4 weeks while maintaining P2Y12 inhibitors in addition to a non-vitamin K oral anticoagulant or warfarin.There are two recent trials – AUGUSTUS and the ENTRUST-AF PCI trial – that evaluated regimens of apixaban and edoxaban, respectively, that support earlier findings reporting lower bleeding rates in patients maintained on oral anticoagulant plus a P2Y12 inhibitor compared to triple therapy.Of note, none of these trials were specifically powered for ischemic endpoints, but when pooling data from these trials, rates of death, MI and stent thrombosis with dual therapy were similar to those seen in patients on triple therapy.Additionally, all of these patients enrolled in these trials were briefly treated with triple therapy after PCI before the aspirin was discontinued. In the 2021 guidelines, it is noted that analyses of stent thrombosis suggest that 80% of events occur within 30 days of PCI. Thus, it is reasonable to consider extending triply therapy to 1 month after PCI in high risk patients to reduce risk of stent thromboses.In AUGUSTUS, 90% of patients received clopidogrel as their P2Y12 inhibitor Case #2 Synopsis: A man in his mid-50s with a history of peripheral vascular disease with prior SFA stent for chronic limb ischemia, hyperlipidemia, tobacco use, diabetes, and chronic kidney disease presented with a two day history of “reflux” that was worse with exertion and that improved with rest and associated with diaphoresis. He was diagnosed with an NSTEMI. His LHC revealed 99% mid-RCA thrombotic occlusion with moderate disease in the LAD. He underwent thrombectomy and PCI with a single drug-eluting stent to the RCA. We discussed his short-term and long-term antithrombotic therapy Case #2 Takeaways
Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, including the following topics: Prologue (0:00) First-line treatment (3:38) Bispecific antibodies (34:41) CAR T-cell therapy (48:21) CME information and select publications
Featuring perspectives from Drs Jeremy Abramson, Sonali Smith and Jason Westin, moderated by Dr Neil Love.
Host: Ajay K. Singh, MBBS, FRCP, MBA Guest: Kirsten L. Johansen, MD Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.
CME credits: 1.00 Valid until: 19-10-2023 Claim your CME credit at https://reachmd.com/programs/cme/challenging-cases-in-ckd-anemia-the-kidneys-and-heart-as-linked-parts/14128/ Anemia in chronic kidney disease (CKD) is persistently undermanaged because current treatments have been linked with an increased risk for major cardiovascular events. They are also injectable or intravenous and definitely invasive, which no doubt limits patient acceptance. Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a novel class of small-molecule oral drugs in late-phase development and under review by the FDA that are poised to provide an alternative treatment paradigm for patients with CKD-related anemia. Physicians and other clinicians who manage patients with anemia in CKD will need to be familiar with these novel agents and the data supporting their use in appropriately selected patients.
It's another session of CardioNerds Rounds! In these rounds, Dr. Natalie Stokes (Formerly FIT at University of Pittsburgh and now General Cardiology Faculty at University of Pittsburgh) and Dr. Karan Desai (formerly FIT at University of Maryland and now General Cardiology faculty at Johns Hopkins) join Dr. Rick Nishimura (Professor of Medicine at Mayo Clinic) to discuss the nuances of managing mitral regurgitation through real cases. Dr. Nishimura has been an author or Chair of the ACC/AHA valve guidelines going back 20 years and has been recognized internationally as one of the world's best educators, so you don't want to miss the #NishFactor on these #CardsRounds! Audio editing by CardioNerds academy intern, Pace Wetstein. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Mitral Regurgitation with Dr. Rick Nishimura Case #1 Synopsis: A man in his 70s with a history of non-ischemic cardiomyopathy (last known LVEF 15-20%) and atrial fibrillation, presented with decompensated heart failure in the setting of moderate to severe mitral regurgitation. He was diuresed, transitioned to GDMT, and referred to cardiac rehabilitation. Over the next 6 months, he continued to have debilitating dyspnea (NHYA Class IIIa) and his outpatient physicians were limited on titrating GDMT further due to hypotension. A TEE was done which demonstrated EF 15%, severe MR by color and quantitation (EROA of 0.5 cm2; Regurgitant Volume of 65 mL), systolic flow reversal in the pulmonary vein and severe tricuspid regurgitation. We were asked how we would approach this case Case #1Takeaways In attempting to keep the evaluation of chronic mitral regurgitation relatively simple, we should ask ourselves three primary questions: (1) What is causing the MR; (2) How much MR is there; and (3) What is the hemodynamic consequence of the MR.To the first question of what is the etiology of the MR – a simple framework is to think of the etiology as an issue of the valve (primary) or an issue of the ventricle/atria (secondary). There is further classification that can be made based on the Carpentier Classification which speaks to the valve leaflet movement and position (normal leaflet motion, excessive leaflet motion [e.g., prolapse], or restricted in systole and/or diastole [e.g., rheumatic heart disease]).During rounds, Dr. Nishimura provided some historical context in that the original valve guidelines had recommendations for intervention on primary mitral regurgitation and not secondary – given that it is considered a disease of the ventricle. Trials like the COAPT trial have greatly shifted our practice in treating secondary mitral regurgitation. Though, we have to be familiar with which patients with secondary MR would truly derive benefit from mitral valve interventionIn regards to the COAPT trial, patients with moderate to severe (3+) or severe (4+) mitral regurgitation who remained symptomatic despite maximally tolerated guideline-directed medical therapy (GDMT) were included. Dr. Nishimura makes the point that about one-third of patients intended to be enrolled in the trial were not included because they improved so much on GDMT. And thus, when evaluating patients for consideration of mitral valve intervention in secondary MR – a...
It's another session of CardioNerds Rounds! In these rounds, Dr. Stephanie Fuentes (EP FIT at Houston Methodist) joins Dr. Hugh Calkins (Professor of Medicine and Director of the Electrophysiology Laboratory and Arrhythmia Service at Johns Hopkins Hospital) to discuss the nuances of atrial fibrillation (AF) management through challenging cases. As an author of several guideline and expert consensus statements in the management of AF and renowned clinician, educator, and researcher, Dr. Calkins gives us many pearls on the management of AF, so don't miss these #CardsRounds! This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Challenging Cases - Atrial Fibrillation with Dr. Hugh Calkins Case #1 Synopsis: A woman in her mid-60s presents with symptomatic paroxysmal atrial fibrillation (AF). An echocardiogram has demonstrated that she has a structurally normal heart. Her primary care doctor had started Metoprolol 50 mg twice a day but she has remained symptomatic. In office, an EKG confirms AF, but she converts to sinus while there. She is seeking advice to prevent further episodes and in general wants to avoid additional medications Case #2 Takeaways We discussed several potential options for treatment. Amongst the first things we discussed was amiodarone. In a patient of this nature without structural heart disease and under the age of 70, Dr. Calkins discussed that he would probably consider amiodarone as a 2nd line option. While amiodarone may be effective in maintaining sinus rhythm in comparison to other antiarrhythmic medications like sotalol, flecainide, and propafenone, it does have significant toxicity.If antiarrhythmic drugs (AAD) were to be considered, we also discussed the options of dofetilide versus sotalol. Dofetilide typically requires inpatient initiation due to the risk of QT prolongation and Torsades. Since women tend to have longer corrected QT (QTc) intervals, high dose dofetilide may be more proarrhythmogenic in women. Though, Dr. Calkins noted that many patients don't tolerate sotalol due to fatigue and generally dofetilide is well tolerated.When it comes to the “pill in the pocket” approach, Dr. Calkins noted that its utility is more so in patients with persistent AF that is known to not stop on its own. For instance, an individual who has AF a few times a year that is persistent may benefit from flecainide or propafenone (“in the pocket”) instead of being brought in for an electrical cardioversion. In this scenario, the first time one of these agents is used, the patient ought to be closely monitored. For our patient, her episodes were too frequent and self-terminating for a “pill in the pocket” approach to be effective.Current guideline recommendations for catheter ablation include a Class IA recommendation for patients with paroxysmal AF refractory to AADs, and a Class IIA recommendation as first-line therapy for patients with paroxysmal AF.In the 2020 ESC Atrial Fibrillation Guidelines, catheter ablation is given a Class IA recommendation to improve symptoms of AF recurrences in patients who have failed or are intolerant of one Class I or III AADs. For patients who have failed or have been intolerant of beta blocker alone for rhythm control,
It's another session of CardioNerds Rounds! In these rounds, Co-Chair, Dr. Karan Desai (previous FIT at the University of Maryland Medical Center, and now faculty at Johns Hopkins) joins Dr. Ryan Tedford (Professor of Medicine and Chief of Heart Failure and Medical Directory of Cardiac Transplantation at the Medical University of South Carolina in Charleston, SC) to discuss the nuances of managing pulmonary hypertension in the setting of left-sided heart disease. Dr. Tedford is an internationally-recognized clinical researcher, educator, clinician and mentor, with research focuses that include the hemodynamic assessment of the right ventricle and its interaction with the pulmonary circulation and left heart. This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Cases discussed and Show Notes • References • Production Team CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Challenging Cases - Nuances in Pulmonary Hypertension Management with Dr. Ryan Tedford Case #1 Synopsis: A woman in her late 30s presented to the hospital with 4 weeks of worsening dyspnea. Her history includes dilated non-ischemic cardiomyopathy diagnosed in the setting of a VT arrest around 10 years prior. Over the past 10 years she has been on guideline-directed medical therapy with symptoms that had been relatively controlled (characterized as NYHA Class II), but without objective improvement in her LV dimensions or ejection fraction (LVEF 15-20% by TTE and CMR and LVIDd at 6.8 cm). Over the past few months she had been noting decreased exercise tolerance, worsening orthopnea, and episodes of symptomatic hypotension at home. When she arrived to the hospital, she presented with BP 95/70 mmHg, increased respiratory effort, congestion and an overall profile consistent with SCAI Stage C-HF shock. In the case, we go through the hemodynamics at various points during her hospitalization and discuss options for management including medical therapy and mechanical support. The patient was eventually bridged to transplant with an Impella 5.5. Initial Hemodynamics Right Atrium (RA) Pressure Tracing: Right Ventricle (RV) Pressure Tracing: Pulmonary Artery (PA) Pressure Tracing: Pulmonary Capillary Wedge Pressure (PCWP) Tracing: Case 1 Rounding Pearls One of the first points that Dr. Tedford made was thinking about our classic frameworks of characterizing acute decompensated heart failure, specifically the “Stevenson” classification developed by Dr. Lynne Stevenson that phenotypes patients along two axes: congestion (wet or dry) and perfusion (warm or cold). Dr. Tedford cautioned that young patients may not fit into these classic boxes well, and that a normal lactate should not re-assure the clinician that perfusion is normal.In reviewing the waveforms, Dr. Tedford took a moment to note that besides just recording the absolute values of the pressures transduced in each chamber or vessel, it is critical to understand the morphology of the tracings themselves. For instance, with the RA pressure tracing above, there is no respiratory variation in the mean pressure. This is essentially a “resting Kussmaul's sign,” which is typically indicative of significant RV dysfunction. Thus, even though our echocardiogram in this case did not necessarily show a significantly dilated RV with mildly reduced longitudinal function (T...
It's another session of CardioNerds Rounds! In these rounds, Co-Chairs, Dr. Karan Desai and Dr. Natalie Stokes and Dr. Tiffany Dong (FIT at Cleveland Clinic) joins Dr. Randall Starling (Professor of Medicine and Director of Heart Transplant and Mechanical Circulatory Support at Cleveland Clinic) to discuss the nuances of guideline directed medical therapy (GDMT) through real cases. As a past president of the Heart Failure Society of America (HFSA) and author on several guidelines, Dr. Starling gives us man pearls on GDMT. Come round with us today by listening to the episodes and joining future sessions of #CardsRounds! This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Cases discussed and Show Notes • References • Production Team CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - CardioNerds Rounds: Challenging Cases - Modern Guideline Directed Therapy in Heart Failure with Dr. Randall Starling Case #1 Synopsis: A man in his 60s with known genetic MYPBC3 cardiomyopathy and heart failure with a reduced ejection fraction of 30% presents with worsening dyspnea on exertion over the past 6 months. His past medical history also included atrial fibrillation with prior ablation and sick sinus syndrome with pacemaker implantation. Medications are listed below. He underwent an elective right heart catheterization prior to defibrillator upgrade for primary prevention. At the time of right heart catheterization, his blood pressure was 153/99 with a heart rate of 60. His RHC demonstrated a RA pressure of 15mmHg, RV 52/16, PA 59/32 (mean 41), and PCWP 28 with Fick CO/CI of 2.8 L/min and index of 1.2 L/min/m2. His SVR was 1900 dynes/s/cm-5. He was admitted to the cardiac ICU and started on nitroprusside that was transitioned to a regimen of Sacubitril-Valsartan and Eplerenone. His final RHC numbers were RA 7, PA 46/18/29, PCWP 16 and Fick CO/CI 6.1/2.6. His discharge medications are shown below. Takeaways from Case #1 Unless there are contraindications (cardiogenic shock or AV block), continue a patient's home beta blocker to maintain the neurohormonal blockade benefits. A low cardiac index should be interpreted in the full context of the patient, including their symptoms, other markers of perfusion (e.g., urine output, mentation, serum lactate), and mean arterial pressure before holding or stopping beta blockade. Carvedilol, metoprolol succinate and bisoprolol are all evidence-based options for beta blockers in heart failure with reduced ejection fraction.If there is concern of lowering blood pressure too much with Sacubitril/Valsartan, one method is to trial low dose of valsartan first and then transition to Sac/Val. Note, in the PARADIGM-HF trial, the initial exclusion criteria for starting Sac/Val included no symptomatic hypotension and SBP ≥ 100. At subsequent up-titration visits, the blood pressure criteria was decreased to SBP ≥ 95.In multiple studies, protocol-driven titration of GDMT has shown to improve clinical outcomes, yet titration remains poor. The following image from Greene et al. in JACC shows that in contemporary US outpatient practices that GDMT titration is poor with few patients reaching target dosing. Case #2 Synopsis: A 43 year-old male with a past medical history of familial dilated cardiomyopathy requiring HVAD placement two years prior now comes in with low flow alarms.
CardioNerds Rounds Co-Chairs, Dr. Karan Desai and Dr. Natalie Stokes and CardioNerds Academy Fellow, Dr. Najah Khan, join Dr. Martha Gulati – President-Elect of the American Society for Preventive Cardiology (ASPC) and prior Chief of Cardiology and Professor of Medicine at the University of Arizona – to discuss challenging cases in cardiac prevention. As an author on numerous papers regarding cardiac prevention and women's health, Dr. Gulati provides many prevention pearls to help guide patient care. Come round with us today by listening to the episodes now and joining future sessions of #CardsRounds! This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Cases discussed and Show Notes • References • Production Team CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Challenging Cases of Challenging Cases of Cardiovascular Prevention with Dr. Martha Gulati Case #1 Synopsis: A 55-year-old South Asian woman presents to prevention clinic for an evaluation of an elevated LDL-C. Her prior history includes hyperlipidemia, hypertension, obesity, and pre-eclampsia. She was told she had “high cholesterol” a few years prior and would need medication. She started exercising regularly and cut out sweets from her diet. Before clinic, labs showed: Total Cholesterol (mg/dL) of 320, HDL 45, Triglycerides 175, and (directly measured) LCL-C 180. Her Lipoprotein(a) is 90 mg/dL (ULN being ~ 30 mg/dL). Her HbA1C is 5.2% and her 10-year ASCVD Risk (by the Pooled Cohorts Equation) is 5.4%. Her recent CAC score was 110. She prefers not to be on medication and seeks a second opinion. Takeaways from Case #1 As Dr. Gulati notes, in the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, South Asian ethnicity is considered a “risk enhancing factor.” The pooled cohort equations (PCE) may underestimate risk in South Asians. Furthermore, risk varies within different South Asian populations, with the risk for cardiovascular events seemingly higher in those individuals of Bangladeshi versus Pakistani or Indian origin. There are multiple hypotheses for why this may be the case including cultural aspects, such as diet, physical activity, and tobacco use. A better understanding of these factors could inform targeted preventive measures.In the same 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease mentioned above, history of an adverse pregnancy outcome (APO) increases later ASCVD risk (e.g., preeclampsia) and is also included as a “risk-enhancing factor.” Studies have shown that preeclampsia is an independent risk factor for developing early onset coronary artery calcification. Recent data has shown that the risk for developing preeclampsia is not the same across race and ethnicity, with Black women more likely to develop preeclampsia. Black women also had the highest rates of peripartum cardiomyopathy, heart failure, and acute renal failure. After adjustment for socioeconomic factors and co-morbidities, preeclampsia was associated with increased risk of CVD events in all women, the risk was highest among Asian and Pacific Islander women. Listen to Episode #174. Black Maternal Health with Dr. Rachel Bond to learn more about race-based disparities in cardio-obstetric care and outcomes.Our patient thus has multiple risk-enhancing factors to help in shared decision making and personalize her decisio...
Three experts from the US and EU share their strategies for the timely diagnosis of mild cognitive impairment. Credit available for this activity expires: 2/24/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/969018?src=mkm_podcast_addon_969018
Dr. James Roberts gives us a look into challenging cases in the ER and what you need to know. Our Advanced EM Boot Camp Course focuses on the in-depth topics that will help you become a master practitioner. Fully CME accredited and guaranteed to help you provide the best care for your patients. Use Code: Thanks15 at checkout to get 15% off until Jan 1 2022!Learn more at https://courses.ccme.org/course/advancedbootcamp
CardioNerds Rounds Co-Chair, Dr. Karan Desai, joins Dr. Michelle Kittleson (Director of Postgraduate Education in Heart Failure and Transplantation, Director of Heart Failure Research, and Professor of Medicine at the Smidt Heart Institute at Cedars-Sinai) to discuss challenging cases of hypertrophic cardiomyopathy. As a guideline author on the 2020 ACC/AHA Hypertrophic Cardiomyopathy Guidelines, Dr. Kittleson shows us how the latest evidence informs our management of HCM patients, while sharing many #Kittlesonrules and pearls on clinical care. Come round with us today by listening to the episodes now and joining future sessions of #CardsRounds! This episode is supported with unrestricted funding from Zoll LifeVest. A special thank you to Mitzy Applegate and Ivan Chevere for their production skills that help make CardioNerds Rounds such an amazing success. All CardioNerds content is planned, produced, and reviewed solely by CardioNerds. Case details are altered to protect patient health information. CardioNerds Rounds is co-chaired by Dr. Karan Desai and Dr. Natalie Stokes. Speaker disclosures: None Cases discussed and Show Notes • References • Production Team CardioNerds Rounds PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Show notes - Hypertrophic Cardiomyopaty Cases Case #1 Synopsis: Two non-white brothers in their early 20s come to clinic to establish care. They have no cardiopulmonary symptoms, normal EKGs and normal echos, but there was a possible family history of HCM. Their mother had LV hypertrophy and underwent septal myectomy, but she could not afford genetic testing and was no longer in the patients' lives. The path report suggested “myocyte hypertrophy without disarray or bundles of myocytes.” How would you advise these patients regarding screening and surveillance? Listen to #CardsRounds for the full details! Quotes from Case #1: “Let's take a walk down memory lane and let's get to our evolution of understanding hypertrophic cardiomyopathy… [our understanding] follows the parable of the six blind men and the elephant. Each of the six blind man approached it from different angles, its tusk, its ear, its tail, and they all try to convince each other what an elephant is … because none of them can see the big picture.” Dr. Kittleson on the history of HCM and coming to a unifying diagnosis “The next time you are sitting there mashing your teeth because you have to memorize what the HCM murmur does squat to stand, Valsalva, or handgrip … remember you are standing on the shoulder of Giants. They [Drs. Braunwald and Morrow] pioneered surgical myectomy based on physical exam and cath lab findings” Dr. Kittleson on the physical exam guiding HCM management Takeaways from Case #1 Before we round, we think it is important to get on the same page regarding the nomenclature around HCM. Since the original characterization of hypertrophic cardiomyopathy (HCM) more than 60 years ago (see the Braunwald Chronicles for the origin stories!), different terms have been used to describe the disease. These include idiopathic hypertrophic subaortic stenosis, hypertrophic obstructive cardiomyopathy (HoCM), and “burnt out HCM” when heart failure develops.The 2020 guideline committee recommended a common language to avoid confusion: since left ventricular (LV) outflow tract obstruction (LVOTO) occurs in >60% of patients over time, but one-third remain non-obstructive, the recommendation is t0 call the disease state HCM with or without outflow tract obstruction.Dr. Kittleson added that when heart failure develops we should characterize the pathology as HCM with heart failure rather than “burnt out HCM.” Do we use HCM to describe any LV that has thick walls? Some clinicians will use HCM to describe all disease states that can...
How to select the most appropriate biologic for the individual patients with severe asthma. Credit available for this activity expires: 9/23/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/959256?src=mkm_podcast_addon_959256
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Clinical Conundrums in Type 2 Diabetes: Managing Challenging Cases in Primary Care
Featuring slide presentations and related discussion from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics: Evolving Clinical Decision-Making for Patients with ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (0:00) Selection and Sequence of Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer — Hope S Rugo, MD (40:00) New Directions in the Treatment of Triple-Negative and Hereditary Breast Cancer — Melinda Telli, MD (1:39:16) CME information and select publications
A special audio program developed from a series of webinars held in conjunction with the 2021 ASCO Annual Meeting. Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli.
Featuring perspectives from Drs Matthew P Goetz, Hope S Rugo and Melinda Telli, including the following topics: Introduction (0:00) Evolving Clinical Decision-Making for Patients with ER-Positive, HER2-Negative Localized Breast Cancer (7:33) Case: A postmenopausal woman in her mid-50s with ER-positive, PR-negative, HER2-negative pT1cN1 breast cancer — Ruth O'Regan, MD (12:57) Case: A woman in her early 40s with 6-cm ER-positive, HER2-negative localized breast cancer — Reshma Mahtani, DO (15:10) Selection and Sequence of Therapy for ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (34:44) Case: A woman in her mid-50s with ER-positive, PR-negative, HER2-negative mBC — Dr O'Regan (36:33) Case: A woman in her early 50s with ER-positive, HER2-negative mBC — Germline BRCA2 mutation — Dr Mahtani (41:58) Case: A woman in her late 30s with ER-positive, HER2-negative mBC — Germline BRCA1 mutation — Ann Partridge, MD, MPH (46:45) New Directions in the Treatment of Triple-Negative Breast Cancer (TNBC) (53:24) Case: A woman in her early 50s with metastatic TNBC — PD-L1-positive — Dr Partridge (55:50) CME information and select publications
A special audio program developed from a series of webinars held in conjunction with the 2021 ASCO Annual Meeting. Featuring perspectives from Drs Javier Cortes, Erika Hamilton and Ian E Krop.
Featuring perspectives from Drs Erika Hamilton, Ian Krop, and Joyce O'Shaughnessy, including the following topics: Introduction (0:00) Role of Immunotherapy in HER2-Positive Metastatic Breast Cancer (mBC) (1:34) Case: A woman in her mid-50s with ER-positive, HER2-positive mBC enrolled on a clinical trial of nivolumab/ipilimumab — Reshma Mahtani, DO (1:50) Management of HER2-Positive mBC (9:17) Case: A woman in her early 30s with ER-positive, HER2-positive mBC — Ann Partridge, MD, MPH (13:57) Case: A woman in her early 70s with HER2-positive mBC — Dr Mahtani (17:39) Case: A woman in her late 50s with ER-negative, HER2-positive mBC — Ruth O'Regan, MD (21:11) Case: A woman in her early 50s with ER-positive, HER2-positive mBC — Dr Partridge (27:20) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (39:22) Case: A woman in her mid-40s with 5-cm ER-positive, HER2-positive localized breast cancer — Dr Mahtani (44:05) Case: A woman in her early 50s with 4.5-mm ER-positive, HER2-positive breast cancer — Dr O'Regan (49:24) CME information and select publications
Featuring slide presentations and related discussion from Drs Erika Hamilton, Ian Krop, and Joyce O'Shaughnessy, including the following topics: Optimizing the Management of HER2-Positive Metastatic Breast Cancer — Joyce O'Shaughnessy, MD (0:00) Treatment of HER2-Positive Brain Metastases — Erika Hamilton, MD (43:37) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (1:11:33) CME information and select publications
Dr. James Roberts gives us a look into challenging cases in the ER and what you need to know. Our Advanced EM Boot Camp Course focuses on the in-depth topics that will help you become a master practitioner. Fully CME accredited and guaranteed to help you provide the best care for your patients. Learn more at https://courses.ccme.org/course/advancedbootcamp
Wealthy Wellness Biz: Online Business, Branding & Marketing for Wellness Entrepreneurs
Where to next:01. Let us produce your podcast.Book a "Hire Us" Call==> https://www.brandbetterco.com/book-a-call02. Join the Wealthy Wellness Biz Coaching group for $37/moJoin the biz coaching group==> https://girlmeetsbody.krtra.com/t/MXm4IOVx8YCp03. Wellness clients on-demand - Podcasting for your health-based business MASTERCLASSWatch the free masterclass⇒ https://girlmeetsbody.krtra.com/t/WeYXq4shP2Xc04. Grab the "Tools We Love" ToolkitGrab the tools⇒ https://girlmeetsbody.krtra.com/t/BRVzKXa3tLa405. Take the BrandPOP® Quiz and find out what makes your brand POPTake the quiz⇒ https://girlmeetsbody.krtra.com/t/PjrnxheuqACp06. Grab the free BrandPlanner Toolkit Grab the toolkit ⇒https://girlmeetsbody.krtra.com/t/SsfoV6pEKnXc 07. Prefer to connect on Insta? Here's where you can find us. Follow along on Instagram. ==> https://www.instagram.com/brandbetterco/08. Prefer to connect on TikTok? Here's where you can find us. Follow along on TikTok ⇒ https://www.tiktok.com/@wealthywellnessbiz
The Man, the Myth, the NeurologistJoin Dr. Peter Morresey and Dr. Bart Barber as they talk with equine neurologist Dr. Steve Reed.Dr. Reed is well known throughout the world for his expertise in equine neurology, here is your chance to meet him and learn about his rise to veterinary prominence.
"Complementing Evidence With Expert Experience: Challenging Cases in Paroxysmal Nocturnal Haemoglobinuria "
"Complementing Evidence With Expert Experience: Challenging Cases in Paroxysmal Nocturnal Haemoglobinuria "
Episode 01: Paracorporeal Device in Pulmonary Hypertension Host: David Werho, MD Guests: Monica Mafla, NP and Vamsi Yarlagadda, MD (Lucile Packard Children's Hospital). We discuss the use of a paracorporeal support device to bridge a pediatric patient with pulmonary hypertension and RV failure to lung transplant.
Episode 02:Ambulation on VA ECMO Host: David Werho, MD; Guests: Emily Weissler, MD and Vamsi Yarlagadda, MD (Lucile Packard Children's Hospital); Producer: David Werho, MD. We discuss the strategies used to ambulate a pediatric patient with heart failure while on venoarterial extracorporeal membrane oxygenation support (VA ECMO) while waiting for heart transplant.
On my very first episode of my podcast, I had to feature none other than Teddy Willsey aka Strength Coach Therapy. Teddy is a physical therapist based out of Healthy Baller in Rockville, MD, where he specializes in working with athletes and active adults. Through his social media, Teddy has helped revolutionize how sports PT should be done. He continues to push this profession forward and advocate for more growth in the field. On today's episode, Teddy and I discuss a variety of topics we were asked through social media.The topics include:Our storyChanges we would make in the current PT school curriculum One change we would've changed in our careersAdvantages and disadvantages of cash based PT clinicsThe most challenging case we've ever hadHow to decrease re-tear rates in ACL reconstructionsTeddy's IG: @StrengthCoachTherapyCitizen's Athletics IG: @CitizensAthletics1Teddy's website: http://www.TeddyWillsey.comMy IG: @WesleyWang.DPTMy website: www.WesleyWangDPT.comACL Mastermind FAQ: https://wesleywangdpt.mykajabi.com/faqACL Mastermind sign-up: https://wesleywangdpt.mykajabi.com/offers/4yryvWYZ/checkoutOnline personal training: https://www.wesleywangdpt.com/online-personal-trainingIf you enjoyed today's episode, don't forget to subscribe and I'd greatly appreciate you taking the time to write me a review. Please feel free to share this episode on social media and tag me!
Host: Matt Birnholz, MD Guest: Mark G. Lebwohl, MD Here to give us insight into the strategies he uses to personalize therapeutic approaches for his patients with severe psoriasis is Dr. Mark Lebwohl, professor and chairman of the Department of Dermatology at The Mount Sinai School of Medicine.
Rachel Goldberg, JD, Kathleen Powderly, PhD